<DOC>
	<DOCNO>NCT02210364</DOCNO>
	<brief_summary>Phase I Multicenter , Open-label , Clinical Pharmacokinetic Study Lurbinectedin ( PM01183 ) Combination Capecitabine Patients Unresectable Metastatic Breast Cancer ( MBC ) , Pancreatic Cancer ( PC ) Metastatic Colorectal Cancer ( CRC ) determine recommend dose ( RD ) PM01183 combination capecitabine , characterize safety profile , explore feasibility PM01183 dose optimization , characterize pharmacokinetics ( PK ) , obtain preliminary information clinical antitumor activity combination conduct exploratory pharmacogenomic ( PGx ) analysis .</brief_summary>
	<brief_title>Study Lurbinectedin ( PM01183 ) Combination With Capecitabine Patients With Metastatic Breast Cancer ( MBC ) , Pancreatic Cancer ( PC ) Metastatic Colorectal Cancer ( CRC ) .</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<criteria>Voluntarily sign date write informed consent ( IC ) Age 18 75 year Women childbearing potential must pregnancy excluded appropriate testing study entry . Life expectancy â‰¥ 3 month . Patients histologically/cytologically confirm diagnosis unresectable Metastatic Breast Cancer , Pancreatic Cancer metastatic Colorectal Cancer . Three prior chemotherapycontaining line advance disease . Prior treatment PM01183 capecitabine contain therapy advance disease . History within last year presence unstable angina , myocardial infarction , congestive heart failure , clinically relevant valvular heart disease symptomatic arrhythmia asymptomatic ventricular arrhythmia require ongoing treatment . Ongoing chronic hepatopathy origin . Active uncontrolled infection . Patients dyspnea require ongoing oxygen support . Known human immunodeficiency virus ( HIV ) infection . Any major illness , Investigator 's judgment , substantially increase risk associate patient 's participation study . Men woman childbearing potential use effective method contraception</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>